Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 2/20 | 0.82 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.82 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | THPO | P40225 | 2/20 | 0.67 |
| ▸ | MTOR | P42345 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.66 |
| ▸ | SLC29A1 | Q99808 | 6/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.61 |
| ▸ | ABCC1 | P33527 | 6/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7883012 | 0.93 | MEN1 (0.77) | SCN1ASCN2ASCN3ACYP3A4CYP2D6 | |
| Hexobendine SCHEMBL125629 | 0.90 | SCN1A (1.00) | SCN1ASCN2ASCN3ACYP3A4CYP2D6 | |
| Hexobendine SCHEMBL10402178 | 0.89 | SCN1A (0.97) | SCN1ASCN2ASCN3ACYP3A4CYP2D6 | |
| Hexobendine SCHEMBL2459088 | 0.89 | SCN1A (0.97) | SCN1ASCN2ASCN3ACYP3A4CYP2D6 | |
| Hexobendine SCHEMBL317378 | 0.89 | SCN1A (0.97) | SCN1ASCN2ASCN3ACYP3A4CYP2D6 | |
| SCHEMBL23883392 | 0.88 | SCN1A (0.64) | SCN1ASCN2ASCN3ACYP3A4CYP2D6 | |
| SCHEMBL24011967 | 0.87 | SCN1A (0.63) | SCN1ASCN2ASCN3ACYP3A4CYP2D6 | |
| SCHEMBL24011968 | 0.85 | SCN1A (0.60) | SCN1ASCN2ASCN3ACYP3A4CYP2D6 | |
| SCHEMBL27795094 | 0.85 | SCN1A (0.60) | SCN1ASCN2ASCN3ACYP3A4CYP2D6 | |
| SCHEMBL24016822 | 0.84 | SCN1A (0.59) | SCN1ASCN2ASCN3ACYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | SCN1A 755/4885SCN2A 1235/4885SCN3A 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.